Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 10:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2137–2160 of 3,528 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: biospecimen Collection Clear all

Conditions: Biopsy, Fine-needle, Pancreatic Neoplasm
Interventions: Rapid on-site evaluation (ROSE), Histologic evaluation; Diagnostic Test
Lead sponsor: Azienda Ospedaliera Universitaria Integrata Verona; Other
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable HER2-Negative Breast Carcinoma, Locally Advanced Unresectable Hormone Receptor-Positive Breast Carcinoma, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma
Interventions: Abemaciclib, Anastrozole, Biospecimen Collection, Computed Tomography, Diagnostic Imaging Testing, Exemestane, Fludeoxyglucose F-18, Fluorine F 18 Fluoro Furanyl Norprogesterone, Fulvestrant, Gonadotropin-releasing Hormone Analog, Letrozole, Positron Emission Tomography, Tamoxifen, Therapeutic Estradiol; Drug · Procedure · Other + 1 more
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 3
States / cities: St Louis, Missouri • Chapel Hill, North Carolina • Seattle, Washington

Conditions: Neurofibromatosis Type 1
Interventions: Frameshift Array blood sample test; Genetic
Lead sponsor: Children's National Research Institute; Other
Eligibility: 1 Day to 30 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Atlanta, Georgia • Dallas, Texas

Conditions: Retroperitoneal Sarcoma
Interventions: Biopsy, Biospecimen Collection, Computed Tomography, Intensity-Modulated Radiation Therapy, Resection, Spatially-fractionated Radiation Therapy; Procedure · Radiation
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Trauma Injury, Trauma, Critical Illness, Microbiome, Chronic Anemia, Acute Blood Loss Anemia
Interventions: Data and tissue collection; Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 100 Years
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: Gainesville, Florida

Conditions: Tobacco Cessation, Electronic Nicotine Delivery Systems
Interventions: Vaping - Fruit flavored ENDS, Biospecimen Collection, Vaping - tobacco flavored ENDS; Other · Procedure
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 21 Years and older
Enrollment: 286 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Cervical Cancer, Human Papillomavirus Infection
Interventions: Telephone Recall, Mailed HPV Self-Sampling Kit, Patient Navigation; Behavioral
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 30 Years to 65 Years · Female only
Enrollment: 2,474 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pancreatic Tumors
Interventions: EUS Guided Fine Needle Aspiration, EUS Guided EchoBrush Sampling; Procedure
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years to 85 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Glioblastoma, Malignant Solid Neoplasm
Interventions: Biospecimen Collection; Procedure
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Acute Myeloid Leukemia
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Cyclophosphamide, Echocardiography Test, Electronic Health Record Review, Multigated Acquisition Scan, Mycophenolate Mofetil, Reduced-Intensity Transplant Conditioning Procedure, Ruxolitinib, Survey Administration, Tacrolimus; Procedure · Drug · Other
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Healthy Subject, Hematologic and Lymphocytic Disorder, Hematopoietic and Lymphoid Cell Neoplasm, Immune System Disorder, Malignant Neoplasm
Interventions: Biospecimen Collection, Laboratory Biomarker Analysis, Questionnaire Administration; Procedure · Other
Lead sponsor: University of Southern California; Other
Eligibility: 19 Years and older
Enrollment: 625 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Brain Cancer
Interventions: phlebotomy, biopsy; Procedure
Lead sponsor: Stanford University; Other
Eligibility: Up to 24 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Stanford, California

Conditions: Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Refractory Grade 1 Follicular Lymphoma, Refractory Grade 2 Follicular Lymphoma, Refractory Grade 3a Follicular Lymphoma
Interventions: Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Mosunetuzumab, Polatuzumab Vedotin, Positron Emission Tomography, Questionnaire Administration; Procedure · Biological · Drug + 1 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Duarte, California • Irvine, California

Conditions: HER2-Positive Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
Interventions: Aromatase Inhibition Therapy, Carboplatin, Cytology Specimen Collection Procedure, Docetaxel, Goserelin Acetate, Laboratory Biomarker Analysis, Pertuzumab, Quality-of-Life Assessment, Therapeutic Conventional Surgery, Trastuzumab, Whole Breast Irradiation; Drug · Other · Biological + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2025
U.S. locations: 731
States / cities: Fairbanks, Alaska • Hot Springs, Arkansas • Anaheim, California + 466 more

Conditions: Autism, Inflammation
Interventions: Stool collection, Administration of carbohydrate solution during clinically indicated endoscopy, Questionnaires; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Months to 17 Years
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2017
U.S. locations: 2
States / cities: Boston, Massachusetts • Newton, Massachusetts

Conditions: Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Biospecimen Collection, Bone Scan, Cabazitaxel, Carboplatin, Chest Radiography, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Prednisone; Procedure · Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older · Male only
Enrollment: 528 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2034
U.S. locations: 174
States / cities: Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 129 more

Conditions: Localized Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
Interventions: Biospecimen Collection, Computed Tomography, CT-guided Stereotactic Body Radiation Therapy, Inter-fraction Adaptation of Treatment Plan, Magnetic Resonance Imaging, MRI-guided Stereotactic Body Radiation Therapy, Survey Administration; Procedure · Radiation · Other
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Infections, Human Immunodeficiency Virus and Herpesviridae
Interventions: Dolutegravir 50 mg tablet, Dolutegravir 50 mg oral granules; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Lung Cancer
Interventions: Not listed
Lead sponsor: bioAffinity Technologies Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2025
U.S. locations: 3
States / cities: Summit, New Jersey • Albuquerque, New Mexico • San Antonio, Texas

Conditions: Metastatic Malignant Solid Neoplasm
Interventions: Biospecimen Collection, Computed Tomography, Stereotactic Body Radiation Therapy; Procedure · Radiation
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Prostate Cancer
Interventions: Pasritamig; Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Diarrhoea Predominant Irritable Bowel Syndrome, IBS
Interventions: endoscopy for tissue biopsy, Blood Sample, Stool Sample; Procedure · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Ischemic Heart Disease (IHD), Cardiac Magnetic Resonance Imaging, Myocardial Blood Flow
Interventions: Quantitative Myocardial Blood Flow Evaluation, Qualitative Myocardial Blood Flow Evaluation, Gadavist, Vasodilator, Blood draw for the laboratory assessment; Diagnostic Test · Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 35 Years to 85 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 13
States / cities: San Francisco, California • Louisville, Kentucky • Boston, Massachusetts + 9 more

Conditions: Breast Neoplasms
Interventions: ForeCYTE Breast Aspirator; Device
Lead sponsor: Atossa Therapeutics, Inc.; Industry
Eligibility: 20 Years to 75 Years · Female only
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: New Hyde Park, New York

Search by objective public record fields.

EUS-FNB With ROSE Vs. EUS-FNB Without ROSE

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Frameshift Peptides of Children With NF1

Proton-Spatially Fractionated Radiotherapy and Standard Radiation Therapy for the Treatment of Newly Diagnosed Retroperitoneal Soft Tissue Sarcoma

The Role of Brain-Bone Marrow-Gut Interaction Following Major Trauma

Flavored Electronic Nicotine Delivery Systems to Lower Smoking and Exposure to Tobacco Toxicants Among Cigarette Smokers Interested in Quitting, REFLECT Trial

Prospective Evaluation of Self-Testing to Increase Screening

Evaluation of Image-guided Brushing of Pancreatic Cyst Wall in Diagnosis of Cystic Pancreatic Tumors

Analysis of Cell Count, Viability, and Immunogenicity of Discarded Newly Diagnosed Glioblastoma Tissue or Solid Tumor Tissues

Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation

Collection of Immunology Specimens From Patients With Cancer or Blood Disorders, and Healthy Volunteers

Molecular Genetic Studies of Childhood Brain Tumors and Blood Samples

Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma

Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

Intestinal Inflammation and Carbohydrate Digestion in Autistic Children

Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body

Image-Guidance and Online Adaptation With Stereotactic Body Radiation Therapy for the Treatment of Localized Prostate Cancer, MANTICORE Trial

Relative Bioavailability Study of a Pediatric Granule Formulation of Dolutegravir

Collection of Sputum and Labeling for Lung Cancer

Spatiotemporal Stereotactic Body Radiation Therapy for the Treatment of Patients With Polymetastatic Solid Tumors

Testing Pasritamig Before Surgery for the Treatment of Localized Prostate Cancer

Analyzing IBS to Identify Biomarkers and Microbiome Signatures

The Multicenter Stress Cardiac Magnetic Resonance Quantitative Perfusion Imaging in the United States Study

ForeCYTE Breast Aspirator for Sample Collection and Cytological Testing of Nipple Aspirate Fluid